Features | Partner Sites | Information | LinkXpress
Sign In
RANDOX LABORATORIES
FOCUS DIAGNOSTICS, INC.
AB Sciex

Next Gen Sequencing Generates High Quality Data

By Labmedica International staff writers
Posted on 03 Jan 2012
A leader in clinical diagnostics and genomic services has officially launched its Next-Gen sequencing services.

Scientists have a wide range of sequencing read options ranging from 36 base pair (bp) singleton to 150 bp paired-end reads. The system is capable of generating over 2 gigabyte (GB) data per run with a high percentage of bases over Q30.

The high data yield and superior quality allows scientists to conduct a wide variety of sequencing applications including: highly multiplexed polymerase chain reaction (PCR) amplicon sequencing, small genome sequencing and de novo sequencing, small RNA sequencing, targeted resequencing, and 16S metagenomics.

Ambry Genetics (Aliso Viejo, CA, USA) has officially launched their Next-Gen sequencing services Illumina MiSeq. Ambry Genetics has been an adapter of Illumina (San Diego, CA, USA) sequencing systems for several years and has extensive experience as a Certified Service Provider processing thousands of samples. The Illumina MiSeq uses the same established reversible-terminator sequencing by synthesis chemistry as the HiSeq2000.

"The MiSeq is a fully integrated sequencing platform enabling up to 2 GB of sequencing data using Illumina's established and reliable TruSeq technology. The quick run time and high data yield make the system ideal for amplicon and targeted resequencing projects," said Dr. Aaron Elliott, Director of Genomic Services.

Ambry Genetics is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified commercial clinical laboratory. It has become a leader in providing genetic services focused on clinical diagnostics and genomic services, particularly sequencing and array services.

Related Links:
Ambry Genetics
Illumina



DiagCor Bioscience
DRG International
77 ELEKTRONIKA
comments powered by Disqus
Life Technologies

Channels

Clinical Chemistry

view channel

Heart Attack Biomarkers Accurate in Chronic Kidney Disease Patients

Two blood peptide biomarkers that are indicators of heart attack in the general population also provide critical information regarding heart status in chronic kidney disease patients. High-sensitivity troponin T (hsTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) strongly predict heart failure (HF) in the... Read more

Industry News

view channel

GlaxoSmithKline Boosts Global Cancer Testing With GE Healthcare Deal

The new agreement between GE Healthcare-subsidiary Clarient (Aliso Viejo, CA, USA) and GlaxoSmithKline (GSK; Brentford, UK) will create a force in cancer testing, according to Kalorama Information (New York City, NY, USA). The two entities will form a multipurpose, data analytics- and companion diagnostics (CDx)-driven... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.